improv
screen
test
real
time
surveil
residu
risk
transmiss
diseas
canadian
blood
suppli
remain
low
continu
deal
infecti
diseas
emerg
reemerg
chikungunya
babesiosi
hepat
e
well
infecti
diseas
influenza
threaten
secur
blood
suppli
despit
transfusiontransmiss
new
paradigm
transmiss
diseas
prevent
must
becom
cost
effect
scope
use
target
surveil
donor
screen
riskbas
decis
make
dr
margaret
fearon
cb
medic
director
medic
microbiolog
assist
professor
univers
toronto
discuss
current
preval
classic
transfusiontransmiss
infect
tti
cb
blood
donor
new
emerg
infecti
diseas
cb
prepar
manag
new
risk
also
address
new
paradigm
risk
manag
dr
fearon
began
emphas
sever
layer
protect
canadian
blood
suppli
like
reduc
risk
classic
tti
hepat
b
viru
hbv
hepat
c
viru
hcv
human
immunodefici
virus
hiv
human
tlymphotrop
virus
htlv
ii
syphili
success
larg
attribut
intens
donor
test
tti
supplement
donor
educ
deferr
donor
risk
factor
two
latter
approach
reduc
number
donor
windowperiod
infect
contribut
decreas
confirm
transmiss
diseaseposit
allogen
donor
last
decad
canada
notabl
hbv
hcv
thu
residu
risk
tti
low
standard
estim
residu
risk
canada
calcul
use
incid
rate
observ
donor
seroconvers
per
million
donat
hiv
per
million
donat
hcv
per
million
donat
hbv
dr
fearon
note
updat
residu
risk
current
calcul
compar
report
risk
expect
chang
dramat
dr
fearon
next
turn
attent
newer
emerg
infecti
diseas
threaten
blood
suppli
diseas
led
introduct
new
tti
test
paradigm
cb
ie
season
select
test
west
nile
viru
wnv
chaga
diseas
emerg
infect
monitor
eg
babesiosi
hepat
e
chikv
other
influenza
featur
conting
plan
spite
transfusiontransmit
due
potenti
disrupt
blood
donat
health
care
system
emphas
opinion
transmiss
diseas
test
must
contextspecif
account
local
diseas
preval
environment
factor
resourc
alloc
wnv
mosquitoborn
zoonot
arboviru
emerg
north
america
found
transfusiontransmiss
human
febril
ill
occur
wnv
case
patient
seriou
neurolog
symptom
sinc
case
asymptomat
tti
test
primari
mean
prevent
transmiss
univers
donor
test
adopt
use
nucleic
acid
test
nat
howev
given
season
natur
wnv
outbreak
nuanc
test
methodolog
introduc
cb
june
recogn
lack
local
transmiss
winter
month
donor
test
june
novemb
donor
travel
outsid
canada
test
rest
calendar
year
select
test
also
conduct
chaga
diseas
chaga
caus
protozoan
parasit
trypanosoma
cruzi
endem
central
south
america
mexico
estim
million
peopl
infect
increas
northward
immigr
peopl
region
estim
n
peopl
infect
unit
state
american
blood
servic
implement
univers
donor
test
rate
immigr
endem
countri
lower
canada
thu
cb
test
donor
identifi
risk
base
donor
questionnair
consid
high
risk
includ
born
live
endem
countri
mother
matern
grandmoth
born
live
endem
countri
safeti
approach
demonstr
recent
studi
identifi
evid
infect
amongst
donor
without
risk
factor
identifi
questionnair
except
one
unusu
transfus
transmissionvert
transmiss
case
interestingli
select
test
approach
use
wnv
chaga
diseas
cb
repres
chang
univers
test
approach
last
three
decad
sum
test
everyon
everyth
newer
approach
certain
tti
take
account
geograph
locat
season
effect
risk
factor
set
optim
test
strategi
dr
fearon
call
attent
infecti
outbreak
impact
secur
blood
suppli
despit
transfusiontransmiss
cite
sever
acut
respiratori
syndrom
sar
pandem
influenza
exampl
outbreak
diseas
lead
shortag
staff
donor
due
ill
shortag
critic
suppli
conting
plan
necessari
guard
risk
staff
donor
educ
infect
control
procedur
clinic
reassess
donor
deferr
criteria
key
step
must
taken
protect
blood
suppli
context
transfusiontransmiss
diseas
current
monitor
potenti
emerg
threat
safeti
blood
suppli
includ
babesiosi
hepat
e
chikv
dengu
viru
babesiosi
caus
protozoan
parasit
b
microti
b
duncani
other
genu
spread
infect
tick
infect
asymptomat
unrecogn
spectrum
clinic
sever
also
includ
flulik
symptom
rang
sever
ill
death
immunocompromis
babesia
microti
frequent
transfusiontransmit
microbi
pathogen
unit
state
especi
northeast
upper
midwest
state
transfusiontransmit
case
report
unit
state
one
case
report
canada
hepat
e
clinic
similar
hepat
caus
waterborn
outbreak
develop
countri
canada
previous
thought
primarili
diseas
travel
actual
preval
endem
hepat
e
unknown
case
transmiss
transfus
report
north
america
transfus
transmiss
report
endem
countri
recent
unit
kingdom
chikv
dengu
two
virus
common
tropic
spread
mosquito
lead
similar
acut
ill
fever
rash
musclejoint
pain
transfusiontransmit
case
dengu
report
chikv
arriv
caribbean
thu
identifi
threat
north
america
howev
transfus
transmit
case
chikv
report
date
current
malaria
travel
deferr
provid
protect
respect
mani
affect
area
particularli
caribbean
blood
oper
best
prepar
emerg
threat
surveil
conduct
multipl
health
agenc
includ
world
health
organ
center
diseas
control
prevent
intern
societi
infecti
diseas
oper
prome
program
monitor
emerg
diseas
avail
subscrib
prome
internetbas
report
system
dedic
rapid
global
dissemin
inform
transmiss
diseas
public
health
agenc
canada
feder
agenc
respons
transmiss
diseas
surveil
canada
public
health
agenc
canada
encompass
nation
microbiolog
laboratori
collabor
provinci
public
health
laboratori
provid
diagnost
test
surveil
data
use
guid
cb
decisionmak
test
data
provid
nation
microbiolog
laboratori
travelacquir
chikungunya
use
cb
calcul
estim
risk
case
transfus
transmit
chikv
canada
less
million
collabor
veterinarian
etymologist
ornithologist
may
provid
addit
inform
inform
prepar
reactiv
strategi
emerg
agent
exampl
activ
tick
surveil
report
provid
risk
data
lyme
diseas
also
relev
tickborn
transfusiontransmiss
diseas
babesiosi
recent
babesia
seropreval
studi
b
microti
canadian
blood
donor
demonstr
donor
test
warrant
canada
time
dr
fearon
present
asyetunpublish
data
collabor
cb
transfus
servic
quebec
provinc
hepat
e
seropreval
studi
indic
age
signific
factor
increas
seropreval
hepat
e
absenc
polymeras
chain
reaction
pcr
posit
result
suggest
risk
transfusiontransmiss
hepat
e
canada
extrem
low
howev
preval
data
need
collect
cb
donor
travel
survey
also
provid
data
use
inform
risk
assess
unit
state
remain
popular
travel
destin
cb
blood
donor
nearli
respond
report
travel
caribbean
donor
travel
survey
data
allow
cb
estim
potenti
donor
loss
assess
riskbenefit
defer
donor
travel
countri
outbreak
challeng
face
blood
oper
synthes
avail
inform
exist
emerg
threat
order
rapidli
make
decis
balanc
risk
cost
safeti
meet
challeng
dr
fearon
suggest
util
allianc
blood
oper
riskbas
decis
make
framework
blood
safeti
fig
riskbas
decis
make
framework
framework
health
sector
focu
aid
evidencebas
decis
use
risk
assess
tool
account
multipl
sector
includ
decis
make
process
use
approach
also
repres
paradigm
shift
blood
oper
away
zerorisk
one
use
decisionmak
process
integr
evid
ethic
social
valu
econom
public
expect
histor
context
broader
health
care
prioriti
emerg
infecti
diseas
unpredict
emerg
infecti
diseas
eid
global
issu
demand
intern
surveil
effort
horizon
scan
import
eid
toolkit
provid
use
framework
manag
infecti
threat
blood
suppli
dr
roger
dodd
secretari
gener
intern
societi
blood
transfus
present
perspect
past
current
pathogen
affect
safeti
blood
suppli
object
present
defin
eid
occur
discuss
eid
impact
blood
safeti
review
impact
blood
suppli
manag
examin
current
exampl
emerg
infect
manag
dr
dodd
began
institut
medicin
definit
emerg
infecti
diseas
one
whose
incid
human
increas
within
past
two
decad
threaten
increas
near
futur
institut
medicin
elabor
emerg
may
due
spread
new
agent
recognit
infect
present
popul
gone
undetect
realiz
establish
diseas
infecti
origin
emerg
may
also
use
describ
reappear
reemerg
known
infect
declin
incid
eid
often
origin
animalhuman
interact
prime
exampl
variant
creutzfeldtjakob
diseas
vcjd
probabl
result
human
consumpt
meat
anim
infect
bovin
spongiform
encephalopathi
also
call
mad
cow
diseas
estim
approxim
current
eid
zoonos
caus
class
pathogen
agent
virus
bacteria
parasit
prion
spread
sever
mode
transmiss
fecalor
sexual
contact
etc
infect
emerg
varieti
reason
pathogen
may
undergo
speci
jump
case
hiv
sar
environment
chang
global
warm
may
increas
incid
rang
eid
dengu
malaria
babesiosi
drug
resist
mutat
may
lead
challeng
control
malaria
hbv
subsequ
spread
human
migrat
travel
contribut
dissemin
cruzi
chaga
diseas
pathogen
chikv
migrat
pattern
bird
reservoir
wnv
also
associ
spread
diseas
certain
part
world
consid
hot
spot
emerg
infecti
diseas
varieti
reason
exampl
china
consid
prime
site
emerg
new
strain
virus
influenza
sar
due
close
proxim
humanhuman
interact
humananim
interact
lead
evolut
anim
viral
strain
novel
strain
infect
human
gener
sens
evolut
potenti
consumpt
wild
meat
meat
nondomest
mammal
reptil
amphibian
bird
care
phylogenet
analysi
simian
human
virus
africa
recogn
hot
spot
hiv
emerg
probabl
due
consumpt
primat
bushmeat
human
urban
poor
sanit
crowd
develop
world
also
link
hepat
e
emerg
although
understand
factor
contribut
specif
eid
transmiss
improv
transmiss
like
multifactori
natur
dr
dodd
emphas
eid
local
global
issu
infect
may
emerg
explos
new
area
appropri
condit
eg
vector
environ
met
case
wnv
dengu
chikv
eid
chaga
diseas
may
expand
slowli
result
popul
movement
becom
constrain
new
environ
tickborn
infect
caus
babesia
unit
state
may
constrain
region
infect
character
direct
human
human
transmiss
may
spread
worldwid
differ
rate
depend
mode
transmiss
rapid
respiratori
spread
influenza
sar
slower
sexual
transmiss
hiv
despit
understand
infecti
diseas
transmiss
emerg
diseas
remain
larg
unpredict
understand
eid
may
spread
human
travel
anim
contact
allow
us
understand
probabl
acquir
infect
specif
condit
met
allow
us
predict
infecti
diseas
emerg
unpredict
requir
regular
surveil
hemovigil
effort
place
around
world
diseas
surveil
mani
challeng
warn
signal
may
help
focu
effort
better
monitor
diseas
spread
warn
signal
may
includ
diseas
outbreak
particularli
suscept
popul
immunocompromis
andor
bloodborn
natur
diseas
emerg
infect
impact
blood
safeti
dr
dodd
note
epidem
occur
minut
proport
attribut
transfus
exampl
hiv
case
transfusiontransmit
hiv
epidem
similarli
wnv
case
establish
tti
word
outbreak
like
start
transfus
transfus
patient
necessarili
like
acquir
infect
gener
popul
infecti
diseas
consid
transfusiontransmiss
diseas
certain
pathogenrel
recipientrel
characterist
present
first
pathogen
must
asymptomat
bloodborn
phase
hepat
b
may
either
acut
chronic
second
pathogen
must
abl
surviv
donat
blood
process
storag
procedur
includ
temperatur
chang
leukoreduct
centrifug
third
diseas
must
transmiss
intraven
rout
fourth
recipi
suscept
infect
fifth
diseas
must
recogniz
entiti
recipi
symptom
appear
next
dr
dodd
turn
attent
impact
eid
blood
suppli
manag
aabb
publish
list
eid
interest
eid
categor
base
threat
pose
transfus
safeti
level
regulatori
concern
lack
effect
intervent
amount
public
concern
top
prioriti
assign
pathogen
toward
intellectu
futur
resourc
focus
dengu
virus
babesia
speci
prion
caus
human
vcjd
list
also
includ
chikv
plasmodium
speci
cruzi
human
parvoviru
hiv
hepat
e
eid
toolkit
fig
subsequ
develop
framework
guid
health
profession
public
health
offici
triag
manag
infecti
threat
blood
suppli
eid
toolkit
present
varieti
method
eid
surveil
key
question
ask
threat
suspect
potenti
cours
action
base
situat
riskbas
decisionmak
framework
riskbas
decisionmak
framework
design
allianc
blood
oper
help
blood
oper
identifi
assess
act
commun
risk
decis
relat
blood
safeti
flexibl
tool
object
optim
safeti
blood
suppli
recogn
elimin
risk
possibl
alloc
resourc
proport
magnitud
serious
risk
effect
intervent
reduc
risk
assess
incorpor
social
econom
ethic
factor
may
affect
decis
risk
includ
among
pathogen
identifi
aabb
report
sever
agent
activ
monitor
region
global
level
due
increas
report
transfusiontransmit
case
poor
prognosi
immunocompromis
transfus
recipi
lack
effect
prevent
strategi
babesia
speci
classifi
top
prioriti
futur
blood
suppli
safeti
effort
unit
state
prion
vcjd
monitor
close
donor
screen
success
prevent
spread
donor
pool
prion
current
investig
potenti
relationship
proteinfold
diseas
alzheim
diseas
although
respiratori
infect
eg
middl
east
respiratori
syndrom
coronaviru
transfusiontransmiss
disrupt
donor
avail
organiz
aspect
blood
collect
donat
system
dr
dodd
expand
upon
wnv
ad
american
insight
earlier
provid
canadian
context
dr
fearon
west
nile
fever
caus
flaviviru
transmit
culicin
mosquito
viru
spread
southern
europ
africa
middl
east
india
arriv
unit
state
wnv
endem
continent
us
canada
experi
wnv
us
demonstr
import
infect
overwhelm
unpredict
wnv
consid
stabl
diseas
elsewher
world
north
america
experienc
explos
outbreak
infect
individu
public
concern
high
wnv
previous
unknown
north
america
spread
rapidli
across
contin
via
infect
bird
human
via
mosquito
although
human
human
transmiss
possibl
potenti
transfusionassoci
transmiss
donat
occur
period
presymptomat
viremia
nat
pool
donor
sampl
offer
rapid
rout
test
like
north
american
blood
oper
cb
test
donor
pool
pool
test
posit
individu
donor
test
initi
nat
initi
us
case
transfusiontransmit
wnv
rare
encount
horizon
scan
effort
activ
monitor
potenti
eid
dr
dodd
describ
sever
emerg
agent
evid
assumpt
may
transfusiontransmit
includ
sever
fever
thrombocytopenia
syndrom
viru
report
transfus
transmiss
tt
q
fever
one
report
tt
definit
evid
hepat
e
viru
good
evid
occasion
tt
vcjd
prion
evid
tt
dr
dodd
focus
two
virus
current
caus
concern
dengu
viru
import
arboviru
like
wnv
flaviviru
spread
mosquito
aed
genu
human
amplifi
host
vaccin
investig
current
vaccin
specif
treatment
vector
control
effect
intervent
estim
million
infect
per
annum
worldwid
case
infect
asymptomat
dengu
virus
found
transfusiontransmit
separ
geograph
cluster
hong
kong
singapor
puerto
rico
brazil
current
fdalicens
test
dengu
rna
chikv
caus
recent
massiv
outbreak
caribbean
coexist
dengu
viru
potenti
threat
north
american
blood
suppli
due
geograph
proxim
donor
travel
emerg
infecti
diseas
toolkit
emerg
infecti
diseas
toolkit
framework
develop
aabb
transfusiontransmit
diseas
emerg
infecti
diseas
subgroup
guid
health
profession
public
health
offici
triag
manag
infecti
threat
blood
suppli
eid
toolkit
present
varieti
method
eid
surveil
key
question
ask
threat
suspect
potenti
cours
action
base
situat
pattern
chikv
recent
appear
caribbean
arriv
north
america
donor
could
defer
exposur
symptom
nat
test
chikv
rna
could
initi
red
cell
plasma
collect
could
even
stop
dr
dodd
state
pathogen
inactiv
like
becom
increasingli
import
prevent
transfusiontransmiss
emerg
agent
american
red
cross
puerto
rico
current
involv
trial
investig
monitor
safeti
intercept
pathogen
inactiv
technolog
ceru
corpor
intercept
recent
approv
fda
use
apheresi
platelet
use
intercept
make
avail
pathogenreduc
apheresi
platelet
could
prevent
interrupt
local
platelet
suppli
area
virus
like
chikv
emerg
ebola
outbreak
west
africa
largest
histori
difficulti
identifi
viru
west
africa
contain
spread
relat
poverti
grow
popul
deforest
lack
healthcar
infrastructur
resourc
fundament
issu
must
address
order
prevent
andor
contain
futur
outbreak
dr
allison
mcgeer
director
infect
control
toronto
mount
sinai
hospit
use
recent
ebola
outbreak
west
africa
provid
thoughtprovok
global
perspect
regard
pathogen
spread
consult
whoiniti
mission
liberia
dr
mcgeer
obtain
firsthand
inform
impress
situat
ground
west
africa
navig
issu
relat
polici
healthcar
setup
ebola
viru
difficult
studi
high
mortal
rate
often
occur
area
difficult
access
due
poor
infrastructur
conflict
polit
turmoil
ebola
infect
seem
emerg
due
interconnect
enzoot
epizoot
cycl
first
sequenc
involv
bat
like
reservoir
host
viru
spread
enzoot
transmiss
within
bat
popul
pool
viru
carrier
transmiss
nonhuman
speci
thought
happen
epizoot
cycl
initi
transmiss
human
involv
contact
infect
bat
speci
hunt
accident
contact
ill
wild
anim
humantohuman
spread
via
direct
close
contact
effici
human
infect
ebola
viru
first
appear
target
immun
system
subsequ
destroy
vascular
system
lead
blood
leakag
initi
attack
dendrit
cell
lead
decreas
interferon
product
macrophag
endotheli
cell
degrad
pattern
result
clinic
present
hemorrhag
hypotens
drop
blood
pressur
follow
shock
death
ebola
outbreak
primarili
affect
guinea
sierra
leon
liberia
west
africa
recent
histori
ebola
epidem
sinc
outbreak
record
subsaharan
africa
lead
hundr
case
death
histor
infect
control
local
commun
isol
patient
show
symptom
howev
west
africa
outbreak
unpreced
scale
dr
mcgeer
provid
eyeopen
overview
health
infrastructur
affect
west
african
countri
guinea
liberia
sierra
leon
popul
million
respect
vs
million
canada
spend
health
total
expenditur
per
capita
us
us
us
us
guinea
liberia
sierra
leon
canada
respect
imbal
mirror
number
doctor
per
popul
guinea
liberia
sierra
leon
respect
compar
unit
state
america
underresourc
public
health
healthcar
deliveri
import
contributor
unpreced
scale
epidem
first
step
epidem
spread
viru
reservoir
west
africa
outbreak
aid
mani
econom
polit
geograph
factor
rel
stabl
period
civil
war
countri
increas
birth
rate
increas
popul
median
age
guinea
liberia
sierra
leon
respect
vs
canada
evergrow
popul
deforest
believ
acceler
frequenc
epizoot
cycl
rich
forest
west
africa
intens
log
last
decad
guinea
rainforest
reduc
liberia
sold
log
right
half
forest
analyst
predict
complet
deforest
sierra
leon
within
next
year
forest
habitat
fruit
bat
ebola
probabl
reservoir
host
loss
habitat
bat
escap
urban
environ
hunt
food
come
contact
human
trigger
frequent
transmiss
viru
dr
mcgeer
person
wit
huge
barrier
effect
control
epidem
hospit
liberia
point
rudimentari
natur
facil
equip
poor
hygien
lack
infrastructur
dispos
hospit
wast
dr
mcgeer
comment
due
lack
resourc
also
form
emerg
plan
base
fight
epidem
complet
lack
lack
resourc
infect
control
person
protect
equip
main
reason
nosocomi
transmiss
affect
healthcar
worker
act
amplifi
spread
viru
commun
epidem
healthcar
worker
infect
believ
die
devast
abil
frontlin
healthcar
worker
control
epidem
led
hospit
closur
poor
gener
infrastructur
hinder
transport
medic
suppli
expertis
isol
rural
area
limit
access
dr
mcgeer
highlight
absenc
public
health
health
care
infrastructur
fundament
issu
abl
fight
diseas
ground
west
africa
global
issu
illustr
fragment
global
health
system
institut
law
strategi
interconnect
experi
outbreak
led
call
reform
worldwid
health
system
architectur
media
report
led
widespread
misunderstand
ebola
outbreak
african
problem
unhelp
perpetu
prejudici
colonialera
stereotyp
dr
mcgeer
took
audienc
evolut
epidem
liberia
peak
augustseptemb
juli
august
number
confirm
case
per
day
increas
ebola
treatment
unit
burial
system
overwhelm
monrovia
liberian
capit
citi
patient
ebola
viru
diseas
manag
home
despit
hospit
overwhelm
ebola
patient
fill
capac
mani
health
care
worker
infect
ultim
led
decis
close
hospit
peak
outbreak
presid
liberia
quarantin
west
point
township
particularli
badli
affect
decis
led
riot
area
similar
action
took
place
part
liberia
consequ
deterior
situat
west
africa
intern
respons
initi
septemb
nongovernment
organ
ground
liberia
contribut
fight
ebola
work
span
wide
rang
activ
includ
set
medic
care
contact
trace
open
orphanag
provid
food
peopl
quarantin
build
road
improv
access
cemeteri
identifi
desludg
septic
tank
ebola
treatment
unit
sourc
suppli
person
protect
equip
ebola
treatment
unit
crisi
respons
also
involv
coordin
intern
respons
unpreced
scale
acceler
vaccin
develop
vaccin
ever
test
human
prior
sever
fasttrack
phase
ii
june
intern
group
scientist
publish
interim
result
openlabel
clusterrandom
ring
vaccin
trial
engin
vesicular
stomat
virusbas
ebola
vaccin
develop
canada
nation
microbiolog
laboratori
ring
vaccin
seek
creat
buffer
protect
around
case
viru
continu
spread
initi
trial
found
recipi
protect
viru
studi
vaccin
trial
vaccin
ongo
improv
coordin
overal
emerg
respons
year
later
outbreak
control
occasion
case
still
appear
liberia
novemb
novemb
declar
end
ebola
viru
transmiss
sierra
leon
day
pass
sinc
second
neg
test
last
confirm
patient
ebola
countri
control
outbreak
achiev
institut
effect
control
quarantin
measur
understand
local
practic
challeng
impact
spread
viru
dr
mcgeer
ad
voic
choru
expert
recommend
coordin
nation
intern
effort
prevent
futur
outbreak
earli
warn
system
develop
connect
local
commun
highrisk
area
provis
clearli
defin
respons
recommend
specif
need
commun
recent
advanc
diagnost
risk
map
mathemat
model
pathogen
genom
sequenc
potenti
improv
substanti
quantiti
qualiti
inform
avail
guid
public
health
respons
outbreak
howev
prevent
remain
extrem
difficult
world
bank
estim
invest
public
health
west
africa
would
prevent
case
west
africa
miss
opportun
eventu
led
costli
emerg
respons
estim
un
mission
ebola
emerg
respons
billion
futur
epidem
control
measur
povertystricken
area
includ
worldwid
respons
team
preapprov
emerg
fund
may
improv
outbreak
respons
address
fundament
issu
poverti
infrastructur
educ
healthcar
workforc
develop
commun
need
outbreak
prevent
sever
approach
product
red
blood
cell
rbc
ex
vivo
exist
demonstr
feasibl
howev
none
yet
conduct
scale
would
allow
replac
donorderiv
rbc
improv
chanc
success
bring
ex
vivo
rbc
clinic
multidisciplinari
approach
integr
plan
requir
navig
long
path
concept
commerci
product
altern
mean
keep
blood
system
safe
pathogen
move
away
current
paradigm
donorderiv
product
topic
address
dr
marc
turner
medic
director
scottish
nation
blood
transfus
servic
professor
cellular
therapi
univers
edinburgh
dr
turner
began
mention
mileston
histori
blood
transfus
highlight
number
event
took
place
adopt
home
citi
edinburgh
scotland
exampl
first
systemat
experi
intraspeci
transfus
carri
john
henri
leacock
studi
edinburgh
time
jame
blundel
univers
edinburgh
medic
school
graduat
credit
conduct
first
success
human
transfus
sever
year
later
sinc
earli
last
centuri
transfus
becom
mainstay
clinic
practic
around
million
rbc
transfus
conduct
annual
worldwid
part
particularli
develop
countri
blood
transfus
safe
howev
limit
remain
includ
suffici
suppli
immunolog
compat
donor
recipi
risk
tti
risk
complic
iron
overload
mani
limit
could
potenti
overcom
product
rbc
transfus
laboratori
dr
turner
talk
focus
human
stem
cell
potenti
use
ex
vivo
gener
rbc
transfus
dr
turner
discuss
biolog
engin
limit
must
overcom
order
ex
vivo
gener
cell
becom
viabl
altern
donorderiv
rbc
first
conclus
observ
stem
cell
mcculloch
till
host
citi
symposium
toronto
stem
cell
capabl
selfrenew
differenti
multipl
lineag
ultim
result
gener
differenti
cell
tissu
variou
type
stem
cell
includ
deriv
embryo
eg
human
embryon
stem
cell
hesc
adult
stem
cell
exampl
hesc
pluripot
unlimit
abil
replic
wherea
adultderiv
hematopoiet
stem
progenitor
cell
hspc
differenti
cell
hematopoiet
immun
system
limit
abil
replic
found
bone
marrow
hspc
morpholog
indistinct
bone
marrow
cell
distinguish
cell
use
flow
cytometri
vivo
hspc
found
hypox
environ
edg
bone
marrow
differenti
move
central
marrow
environ
higher
tension
long
known
place
agarsemisolid
medium
provid
right
cytokin
support
hspc
differenti
along
differ
hematopoiet
lineag
form
granulocytemonocyt
erythroid
coloni
day
cultur
hspc
suspens
use
twophas
cultur
system
sever
advantag
solidphas
cultur
vitro
environ
precis
control
separ
easili
dr
turner
provid
overview
two
stage
cultur
system
use
combin
cytokin
control
cell
differenti
prolifer
use
produc
erythroid
cell
adult
peripher
blood
cell
enucl
process
move
cell
earli
reticulocyt
stage
nucleu
extrud
cell
engulf
macrophag
day
twostag
cultur
popul
consist
approxim
normoblast
earli
reticulocyt
system
demonstr
success
expand
hspc
peripher
blood
bone
marrow
cord
blood
function
rbc
proofsofprincipl
demonstr
rbc
gener
ex
vivo
possibl
process
describ
date
limit
scalabl
yet
constitut
workabl
approach
gener
rbc
transfus
dr
turner
spent
remaind
talk
discuss
two
major
type
challeng
face
ex
vivo
gener
rbc
transfus
biolog
challeng
engineeringlogist
challeng
biolog
point
view
one
major
challeng
determin
best
sourc
deriv
cell
adult
hematopoiet
stem
cell
hsc
one
potenti
sourc
ex
vivo
rbc
limit
replic
capac
could
gener
small
number
unit
rbc
relianc
donor
remain
unlik
hsc
hesc
indefinit
expans
capabl
selfrenew
sourc
much
excit
deriv
first
describ
hesc
pluripotentthey
cultur
indefinit
cell
line
abl
differenti
cell
bodi
includ
hematopoiet
cell
consider
less
ethicallycontroversi
sourc
pluripot
stem
cell
discoveredinduc
pluripot
stem
cell
ipsc
earn
discover
nobel
prize
medicin
initi
gener
takahashi
yamanaka
human
somat
skin
fibroblast
use
four
gene
ipsc
similar
hesc
differenti
three
germ
layer
huge
potenti
regen
medicin
applic
diseas
model
like
hesc
human
ipsc
differenti
hematopoiet
cell
vitro
area
intens
research
dr
turner
provid
overview
system
rbc
deriv
human
pluripot
stem
cell
hpsc
vitro
use
feederserum
free
approach
cytokin
mix
drive
hpsc
hspc
erythroblast
normoblast
eventu
reticulocyt
approxim
time
frame
differenti
process
complex
use
mix
multipl
cytokin
small
molecul
sever
issu
remain
includ
long
differenti
time
fact
hpscderiv
rbc
enucl
result
cell
fragil
difficult
maintain
cultur
hpscderiv
rbc
express
globin
chain
combin
hemoglobin
polypeptid
express
fetal
rbc
oppos
globin
chain
adult
rbc
howev
oxygendeliv
characterist
hpscderiv
rbc
accept
therefor
would
preclud
use
effort
underway
optim
erythrocyt
differenti
enucl
modifi
hemoglobin
adult
form
anoth
approach
hold
promis
immort
multipot
stem
cell
use
wellunderstood
establish
method
condit
immort
hpsc
adult
hspc
achiev
use
human
papilloma
viru
combin
transcript
factor
approach
establish
immort
human
erythroid
progenitor
cell
line
switch
immort
allow
product
enucl
rbc
ex
vivo
approach
sever
benefit
psca
start
materi
process
less
complex
differenti
time
shorter
reduc
cost
relat
cytokin
growth
factor
media
final
rbc
phenotyp
closer
adult
phenotyp
feasibl
approach
produc
enucl
rbc
shown
potenti
drawback
approach
includ
concern
regard
introduct
oncogen
cell
cell
line
stabil
likelihood
abl
meet
good
manufactur
practic
standard
produc
clinic
grade
product
notwithstand
difficulti
involv
potenti
clearli
exist
allow
cultur
rbc
rare
phenotyp
modif
rbc
help
meet
need
hardtomatch
transfus
recipi
first
proofofprincipl
human
transfus
ex
vivo
gener
rbc
cultur
peripher
hsc
conduct
show
posttransfus
surviv
ex
vivo
gener
rbc
singl
healthi
subject
compar
donorderiv
rbc
dr
turner
turn
attent
engin
technolog
need
make
ex
vivo
gener
rbc
viabl
altern
donorderiv
product
key
issu
scaleup
process
control
intensif
dr
turner
describ
use
ambr
bioreactor
technolog
tap
biosystem
part
sartoriu
stedim
biotech
group
approach
optimis
vitro
cultur
environ
stir
tank
bioreactor
matur
technolog
scalabl
wellestablish
product
biotherapeut
allow
precis
control
sever
physicochem
paramet
econom
rapid
develop
screen
varieti
scale
ml
ml
multilit
two
gross
limit
system
effici
first
absolut
densiti
limit
calcul
specif
oxygen
uptak
rate
cell
mass
transfer
coeffici
system
regard
bioreactor
system
perform
well
high
densiti
achiev
potenti
certainli
succeed
scale
need
produc
erythroid
cell
second
limit
media
volumetr
product
liter
mediaunit
blood
volumetr
product
precis
determin
cell
growth
rate
specif
support
capac
mediaconsumpt
supplement
specif
rate
unstabl
supplement
glucos
glutamin
improv
growth
suggest
limit
factor
order
potenti
scaleup
system
limit
factor
need
identifi
current
dr
turner
estim
cost
ex
vivoderiv
rbc
stand
mani
time
cost
donorderiv
rbc
stage
technolog
therefor
like
consid
boutiqu
applic
patient
donorderiv
match
product
difficult
imposs
sourc
gener
applic
mani
challeng
remain
includ
control
genet
epigenet
stabil
cell
line
optim
differenti
pathway
allow
stabl
enucl
effici
differenti
pathway
process
control
multipl
physic
biochem
factor
scale
intensif
control
cost
good
detail
character
product
demonstr
preclin
safeti
efficaci
qualiti
control
regulatori
complianc
design
execut
pivot
clinic
trial
mani
challeng
dr
turner
mention
common
cellbas
therapeut
regard
qualiti
control
product
character
one
advantag
field
year
rbc
product
characterist
inform
knowledg
experi
draw
dr
turner
end
note
sea
chang
level
process
control
would
requir
make
product
ex
vivo
rbc
realiti
dr
turner
outlin
environ
resourc
approach
believ
necessari
order
type
innov
take
place
achiev
commerci
success
includ
multidisciplinar
integr
plan
lengthi
time
line
regard
dr
turner
acknowledg
commit
research
team
funder
work
space
pathogen
test
canada
central
autom
close
regul
feder
govern
ms
nanci
angu
director
test
cb
provid
overview
current
state
test
organ
emphasi
donor
test
focus
test
use
canada
ms
angu
describ
laboratori
test
detect
bloodborn
pathogen
summar
differ
sensit
among
test
current
use
cb
test
site
includ
donor
test
diagnost
servic
nation
test
laboratori
nation
refer
laboratori
qualiti
control
product
laboratori
human
leukocyt
antigen
laboratori
donor
test
includ
transmiss
diseas
test
perform
two
site
calgari
alberta
blood
collect
west
ontario
test
toronto
blood
collect
ontario
east
ontario
test
site
mirrorimag
term
equip
act
backup
site
busi
continu
reason
need
aris
blood
collect
cb
test
number
bloodborn
pathogen
syphili
hbv
hcv
htlv
ii
tabl
sinc
implement
wnv
test
perform
collect
blood
howev
test
perform
season
addit
mandatori
test
perform
collect
blood
test
perform
base
risk
approxim
collect
blood
test
cytomegaloviru
cmv
order
suppli
hospit
demand
base
algorithm
identifi
donor
like
cmvfree
test
chaga
perform
select
base
risk
donat
donor
indic
questionnair
mother
matern
grandmoth
origin
chagasendem
countri
extend
stay
endem
area
greater
six
month
chemiluminesc
assay
perform
use
abbott
prism
platform
detect
surfac
antigen
hepat
b
viru
hbsag
total
antibodi
hepat
b
core
antigen
antibodi
hepat
c
viru
antibodi
group
andor
antibodi
antibodi
human
tlymphotrop
viru
type
andor
human
tlymphotrop
viru
type
ii
antibodi
cruzi
agglutin
assay
perform
beckman
coulter
platform
syphili
infect
identifi
use
microhemagglutin
assay
detect
treponema
pallidum
antibodi
cmv
infect
detect
use
passiv
particl
agglutin
assay
detect
total
cytomegaloviru
antibodi
nat
perform
use
roch
coba
platform
detect
rna
group
rna
hcv
rna
hbv
dna
wnv
rna
sampl
screen
pool
singl
unit
test
perform
select
donat
geograph
region
posit
donat
wnv
identifi
canada
test
platform
requir
approv
health
canada
platform
current
avail
includ
immucor
neo
platform
solid
phase
system
allow
serolog
detect
syphili
cmv
grifol
tigri
platform
use
hemaquebec
perform
nat
detect
hiv
rna
hcv
rna
hbv
dna
wnv
rna
blood
donat
found
serolog
reactiv
confirmatori
test
perform
determin
donor
true
posit
confirmatori
test
either
perform
cb
extern
agenc
within
cb
confirmatori
test
includ
hbsag
neutral
assay
immunoblot
htlv
htlv
ii
hcv
enzym
immunoassay
detect
syphili
confirmatori
test
perform
either
alberta
public
health
laboratori
ontario
public
health
laboratori
chaga
confirmatori
test
perform
nation
refer
centr
parasitolog
montreal
medic
servic
innov
divis
cb
perform
surveil
identifi
bloodborn
pathogen
may
pose
threat
blood
suppli
decid
new
test
need
implement
identifi
new
pathogen
new
equip
requir
replac
equip
end
life
health
canada
licensur
requir
unless
emerg
threat
current
horizon
cb
consid
possibl
introduc
hepat
e
viru
nat
test
babesia
next
gener
sequenc
futur
pathogen
test
next
gener
sequenc
ng
advanc
technolog
approach
involv
sequenc
dna
found
clinic
sampl
innov
bioinformat
approach
requir
minim
comput
time
requir
find
pathogen
dna
sampl
maxim
accuraci
ng
increasingli
use
otherwis
indetermin
clinic
diagnos
track
infecti
diseas
outbreak
detect
novel
pathogen
ng
unlik
play
role
screen
blood
suppli
infecti
diseas
marker
near
medium
term
dr
samia
naccach
associ
specialist
depart
laboratori
medicin
univers
california
san
francisco
ucsf
school
medicin
introduc
attende
use
next
gener
sequenc
metagenom
bioinformat
detect
identif
infecti
agent
dr
naccach
first
point
member
laboratori
dr
charl
chiu
home
ucsfabbott
viral
diagnost
discoveri
center
ucsfavddc
center
work
close
ucsf
clinic
microbiolog
laboratori
provid
advanc
technolog
assist
challeng
problem
infecti
diseas
diagnosi
track
dr
naccach
commenc
present
contrast
classic
dna
sequenc
method
next
gener
sequenc
ng
antihiv
antibodi
group
antibodi
nat
nucleic
acid
test
antihbc
total
antibodi
hepat
b
core
antigen
antihcv
antibodi
hepat
c
viru
antihtlv
iii
antibodi
human
tlymphotrop
viru
human
tlymphotrop
viru
type
ii
select
unit
test
singl
unit
limit
detect
theoret
sensit
calcul
multipli
singl
unit
limit
detect
frederick
sanger
colleagu
invent
method
dna
sequenc
determin
intens
use
scientist
next
year
sanger
sequenc
base
select
partial
incorpor
chaintermin
dideoxyribonucleotid
copi
dna
strand
sequenc
separ
denatur
electrophoresi
readabl
sequenc
ladder
dr
naccach
stress
sanger
sequenc
even
later
high
throughput
version
employ
one
limit
piec
dna
typic
small
dna
sector
amplifi
use
pcr
time
yield
singl
output
sequenc
although
method
suffici
advanc
use
sequenc
first
human
mitochondri
genom
entir
human
genom
robust
pale
comparison
ng
approach
ng
yield
huge
amount
dna
sequenc
parallel
word
mani
sequenc
sampl
analyz
simultan
reason
ng
also
call
deep
massiv
parallel
high
throughput
sequenc
inform
output
thousand
million
sequenc
provid
concurr
matter
hour
ng
made
possibl
metagenom
approach
dna
sequenc
genom
present
clinic
sampl
identifi
approach
use
determin
blood
sampl
contain
human
dna
human
dna
plu
dna
infecti
pathogen
well
identifi
pathogen
sequenc
known
brief
technic
overview
ng
methodolog
provid
dr
naccach
dnarna
present
sampl
first
rapidli
extract
copi
use
pcr
fragment
piec
uniform
length
provid
librari
short
artifici
dna
sequenc
bond
onto
either
end
librari
dna
fragment
adaptor
allow
hybrid
one
strand
modifi
dna
complementari
tether
piec
dna
flow
cell
sequenc
synthesi
use
fluoresc
deoxyribonucleotid
triphosph
build
block
base
ad
grow
chain
posit
note
via
imag
posit
inform
captur
parallel
ng
therefor
provid
gigabyt
datamuch
redund
sequenc
detect
read
multipl
timesto
ensur
suffici
coverag
dna
sequenc
present
sampl
huge
amount
data
first
process
use
algorithm
detect
remov
low
qualiti
read
host
human
genom
sequenc
inform
subtract
remain
dna
assembl
contigu
array
align
overlap
sequenc
compar
refer
genom
known
pathogen
identifi
pathogen
differ
slightli
refer
genom
taxonom
classif
done
determin
recent
variant
diverg
known
sequenc
dr
naccach
stress
approach
work
bacteri
viral
fungal
parasit
pathogen
encod
rnaor
dnabas
genom
prion
proteinbas
pathogen
infect
caus
host
protein
take
patholog
conform
ng
advanc
technolog
approach
fulli
depend
characterist
instrument
employ
dr
naccach
survey
rapid
develop
commerci
deep
sequenc
machin
first
market
roch
sequenc
capabl
read
bp
illumina
ion
torent
produc
instrument
gener
million
billion
read
slightli
shorter
size
bp
similar
overal
run
time
product
work
paradigm
sequenc
synthesi
recent
entri
instrument
field
work
differ
principl
call
nanopor
sequenc
pac
bio
rs
apparatu
oxford
nanopor
technolog
minion
instrument
capabl
smaller
number
read
earlier
machin
read
much
longer
bp
technolog
work
principl
detect
grow
dna
chain
electr
chain
extrud
engin
protein
pore
nanomet
diamet
minion
instrument
amazingli
small
essenti
size
larg
memori
stick
effect
exploit
mountain
dna
inform
produc
ng
clinic
blood
bank
sampl
requir
minim
comput
time
maxim
accuraci
diagnost
output
dr
naccach
cowork
develop
bioinformat
platform
task
call
surpi
sequencebas
ultrarapid
pathogen
identif
platform
necessari
given
size
ng
output
dna
sequenc
size
pathogen
refer
sequenc
databas
fact
pathogen
sequenc
typic
constitut
read
ng
output
present
needl
haystacktyp
problem
achiev
rapid
robust
detect
surpi
employ
two
analyz
program
work
dna
translat
protein
align
use
bacteri
viral
databas
platform
employ
either
fast
comprehens
mode
fast
mode
pathogen
sequenc
identifi
clinic
sampl
minut
hour
comprehens
mode
appropri
detect
novel
pathogen
entir
genom
rule
infect
clinic
complex
case
dr
naccach
note
clinic
signific
respiratori
infect
current
unknown
etiolog
dr
naccach
present
data
compar
time
complet
analysi
ng
data
use
either
surpi
mode
varieti
clinic
sampl
type
serum
took
less
time
analyz
biolog
materi
open
environ
eg
stool
sampl
hiv
spike
plasma
could
detect
minut
either
mode
viral
copi
per
millilit
success
identif
strain
specif
surpi
extens
test
optim
use
clinic
sampl
prior
employ
prospect
clinic
case
seri
carri
ucsf
april
decemb
singlesit
studi
respect
analysi
includ
case
refer
across
unit
state
also
europ
studi
includ
acut
chronic
ill
hospit
patient
clinic
featur
suggest
infecti
diseas
test
neg
candid
agent
dr
naccach
highlight
two
diagnos
achiev
ng
clinic
seri
first
involv
adolesc
boy
whose
fever
headach
evolv
cours
four
month
hydroencephalopathi
forc
physician
induc
coma
stabil
follow
hundr
inconclus
laboratori
test
ng
reveal
presenc
leptospira
santarosai
pathogen
bacterium
cerebrospin
fluid
sampl
view
patient
poor
statu
safeti
specif
treatment
leptospira
ngsbase
diagnosi
incorrect
intraven
penicillin
treatment
commenc
confirm
leptospira
infect
receiv
center
diseas
control
follow
week
treatment
follow
rehabilit
patient
made
full
recoveri
second
case
highlight
speaker
man
underw
bone
marrow
transplant
immunosuppress
treatment
chronic
lymphocyt
leukemia
month
later
develop
tinnitu
partial
deaf
progress
rapidli
accompani
increas
mental
deterior
brain
biopsi
tissu
assess
ng
detect
neuroinvas
astroviru
infect
known
efficaci
therapi
patient
die
month
postng
diagnosi
month
onset
symptom
ng
sampl
answer
turnaround
time
report
hour
first
case
hour
second
substanti
list
differ
pathogen
detect
ucsf
avddc
group
use
ng
differ
biolog
fluid
csf
respiratori
secret
blood
next
present
speaker
latter
categori
agent
includ
pathogen
familiar
transfus
medicineori
audienc
virus
epsteinbarr
viru
cytomegaloviru
west
nile
viru
hepat
virus
e
chikv
viru
chikv
bacterium
pseudomona
aeruginosa
transfer
donor
skin
blood
product
venipunctur
parasit
plasmodium
falciparum
one
caus
agent
malaria
also
includ
ng
detect
list
less
familiar
agent
rna
virus
enteroviru
hantaviru
pegiviru
rhinoviru
c
doublestrand
dna
virus
four
variant
human
herpesvirus
bk
jc
virus
variou
singlestrand
dna
virus
cyclovirida
anellovirida
famili
bacterium
salmonella
typhi
parasit
leishmania
infantum
sensit
ng
underlin
detect
virus
usual
associ
diseas
anellovirida
associ
diseas
immunosuppress
individu
bk
jc
virus
may
part
background
flora
fauna
human
must
discount
arriv
bona
fide
ng
diagnosi
dr
naccach
continu
consider
recent
result
ucsfavddc
group
employ
nanopor
sequenc
ucsf
avddc
particip
research
program
sponsor
oxford
nanopor
technolog
design
probe
optim
capabl
minion
instrument
dr
naccach
report
use
minion
surpilik
bioinformat
platform
call
metapor
plasma
sampl
individu
separ
infect
chikv
ebola
viru
hepat
c
rapidli
identifi
real
time
chikv
ebola
viru
sampl
contain
copiesml
detect
within
minut
data
acquisit
lowertit
hepat
c
viru
copiesml
detect
within
minut
analyz
algorithm
success
identifi
virus
despit
rel
errorpron
natur
sequenc
data
total
sampl
answer
time
less
hour
feat
appar
unpreced
ng
area
dr
naccach
provid
cautionari
tale
illustr
extrem
sensit
ng
involv
parvoviruslik
hybrid
viru
previous
undescrib
novel
viru
relat
circovirida
parvovirida
famili
initi
detect
chines
patient
chronic
seroneg
hepat
unknown
etiolog
ucsfavddc
group
also
found
parvoviruslik
hybrid
viru
ng
hepat
cohort
eventu
realiz
viru
present
commerci
silicatyp
spin
column
use
dna
purificationconcentr
origin
patient
sampl
silic
typic
sourc
cell
wall
diatom
concord
pvh
sequenc
found
environment
metagenom
databas
sampl
taken
north
american
coastal
water
instanc
laboratori
contamin
illustr
extrem
sensit
ng
methodolog
stringenc
must
brought
applic
wrap
present
dr
naccach
discuss
likelihood
ng
would
contribut
directli
blood
donat
screen
assess
outcom
somewhat
improb
near
term
part
blood
donat
screen
current
highli
effect
ng
current
quit
expens
accur
form
lead
dr
naccach
estim
cost
wellcov
ng
studi
around
sampl
use
total
million
sequenc
hiseq
platform
us
shallow
studi
kind
describ
rapid
detect
ebola
chikv
around
sampl
use
total
million
sequenc
miseq
platform
us
howev
estim
truli
take
account
substanti
infrastructur
place
ucsfavvdc
compris
special
equip
sampl
extract
librari
gener
valid
ng
sequenc
extens
comput
analysi
mention
skill
medic
technologist
research
bioinformat
specialist
relev
ng
respect
keep
blood
system
safe
emerg
pathogen
like
lie
determin
pattern
diseas
transmiss
provid
confid
necessari
requalifi
previous
defer
blood
donor
suspect
transmiss
transfus
identifi
rapidli
great
sensit
specif
use
ng
implic
donor
recipi
also
use
gener
epidemiolog
sens
trace
pattern
infect
adapt
speciat
infecti
agent
contribut
ng
clinic
diagnosi
intract
case
public
health
respect
track
understand
diseas
outbreak
alreadi
substanti
like
continu
accumul
exponenti
prospect
use
ng
routin
blood
donat
screen
remain
remot
due
cost
throughput
consider
biolog
impact
pathogen
inactiv
blood
product
qualiti
pathogen
inactiv
pi
blood
product
may
advantag
overcom
limit
current
strategi
eg
assay
sensit
threat
emerg
pathogen
pi
techniqu
bring
two
side
coin
blood
bank
improv
safeti
versu
neg
effect
blood
compon
qualiti
damag
platelet
order
improv
qualiti
pathogeninactiv
blood
product
molecular
mechan
trigger
technolog
need
identifi
pitreat
whole
blood
might
emerg
method
choic
field
dr
peter
schubert
research
associ
canadian
blood
servic
centr
innov
clinic
associ
professor
depart
patholog
laboratori
medicin
univers
british
columbia
focus
talk
need
pi
ensur
safeti
blood
suppli
compar
current
avail
pi
technolog
mechan
action
discuss
potenti
impact
technolog
product
qualiti
dr
schubert
note
blood
safeti
histor
achiev
mitig
known
risk
intervent
donor
screen
univers
donor
test
specif
pathogen
howev
risk
remain
test
detect
limit
current
test
account
unknown
unexpect
pathogen
thu
pi
potenti
improv
safeti
blood
product
prevent
tti
especi
platelet
product
bacteri
contamin
particular
risk
unit
state
intercept
blood
system
ceru
corpor
current
licens
platelet
product
intercept
octapla
product
octapharma
licens
plasma
tabl
canada
current
licens
pi
product
octapla
plasma
three
differ
pi
system
platelet
concentr
current
market
tabl
exploit
fact
pathogen
prolifer
occur
replic
dna
rna
mandatori
step
pathogen
except
prion
use
uv
light
without
photosensit
damag
nucleic
acid
subsequ
prevent
prolifer
pathogen
mani
system
routin
use
mostli
europ
middl
east
mani
jurisdict
regulatori
approv
initi
investig
worldwid
ceru
intercept
blood
system
adopt
system
routin
use
year
hemovigil
data
jurisdict
use
product
highli
favor
support
safeti
efficaci
sever
clinic
trial
pi
technolog
taken
place
underway
includ
eurosprit
look
intercepttr
platelet
concentr
sprint
look
intercepttr
apheresi
platelet
miracl
look
mirasoltr
apheresi
platelet
although
safeti
level
advers
transfus
reaction
favor
pitreat
platelet
one
observ
approxim
platelet
appear
damag
pi
treatment
sprint
miracl
trial
demonstr
lower
mean
posttransfus
count
increment
increas
number
platelet
transfus
lower
correct
count
increment
respect
patient
treat
pi
platelet
prepar
pathogen
reduct
evalu
predict
analyt
rate
score
trial
recent
complet
prospect
random
singleblind
multicent
noninferior
trial
compar
mirasoltr
standard
care
pool
platelet
product
hematooncolog
patient
initi
netherland
novemb
prepar
sponsor
sanquin
blood
suppli
foundat
nation
blood
oper
netherland
financi
support
terumobct
canadian
arm
trial
involv
cb
produc
mirasoltr
pool
platelet
ottawa
manufactur
site
sever
hospit
ontario
account
observ
damag
seen
pi
techniqu
trial
consist
prepar
platelet
pool
netherland
mirasoltr
platelet
contain
donat
five
donor
rather
four
standard
buffi
coat
platelet
product
prepar
cb
although
simpli
increas
platelet
dose
set
straightforward
solut
issu
platelet
damag
seen
pi
dr
schubert
note
mechan
piassoci
damag
unknown
current
literatur
debat
regard
clinic
efficaci
pi
platelet
metaanalysi
bleed
complic
random
control
trial
use
intercept
system
suggest
increas
risk
clinic
signific
bleed
metaanalysi
cochran
collabor
suggest
differ
bleed
pi
platelet
although
conclus
limit
signific
heterogen
studi
thu
elucid
potenti
mechan
import
finetun
system
dr
schubert
provid
overview
effect
qualiti
paramet
platelet
product
three
differ
pi
system
common
trend
neg
impact
routin
qualiti
measur
well
newer
tool
introduc
character
platelet
qualiti
function
howev
magnitud
effect
differ
depend
pi
technolog
amongst
effect
pi
treatment
increas
metabol
apoptosi
develop
platelet
activ
featur
lead
decreas
platelet
respons
vitro
clot
format
furthermor
effect
pi
treatment
novel
aspect
platelet
function
also
extens
investig
studi
show
pidepend
effect
cytokin
mitochondri
dna
microparticl
releas
gener
reactiv
oxygen
speci
initi
signal
cascad
express
profil
mrna
mirna
novel
platelet
featur
might
assist
explain
pieffect
associ
increas
inflamm
cell
damag
apoptosi
transfusionrel
acut
lung
injuri
modul
endotheli
cell
function
addit
studi
effect
pi
proteom
platelet
could
provid
insight
mechan
although
overal
impact
protein
express
profil
rel
small
suggest
pitrigg
modul
protein
activ
final
dr
schubert
work
elucid
signal
cascad
mirasoltr
platelet
reveal
central
role
regul
platelet
activ
apoptosi
develop
besid
platelet
concentr
pitreat
plasma
use
routin
jurisdict
howev
pi
rbc
concentr
challeng
due
high
optic
densiti
requir
larg
amount
uv
light
accordingli
lead
signific
rbc
damag
ceru
system
pi
rbc
demonstr
similar
recoveri
standard
rbc
product
would
meet
canadian
standard
due
decreas
shelf
life
dr
schubert
discuss
pi
whole
blood
may
effici
approach
compar
pi
individu
compon
potenti
benefit
whole
blood
pi
includ
earli
remov
pathogen
protect
transfusionassoci
graft
versu
host
diseas
due
wbc
inactiv
increas
safeti
blood
product
compon
applic
mirasol
technolog
whole
blood
demonstr
efficaci
hiv
trypansoma
cruzi
b
microti
recent
studi
use
mirasol
malaria
inactiv
whole
blood
perform
ghana
howev
reduct
tti
must
balanc
effect
whole
blood
pi
blood
compon
qualiti
studi
vivo
viabil
store
rbc
deriv
mirasoltr
whole
blood
suggest
decreas
viabil
correl
qualiti
variabl
hemolysi
atp
concentr
approach
complement
studi
schubert
colleagu
demonstr
platelet
product
qualiti
seem
less
affect
produc
whole
blood
illumin
compar
platelet
compon
treatment
dr
schubert
conclud
acknowledg
two
side
pi
coin
balanc
must
achiev
safeti
qualiti
research
need
understand
molecular
mechan
lead
chang
qualiti
pi
balanc
potenti
reduct
compon
effect
reduct
tti
ultim
clinic
trial
essenti
come
make
decis
regard
implement
pathogen
inactiv
blood
bank
econom
health
outcom
implic
introduc
new
pathogen
test
inactiv
technolog
order
costeffect
implement
broad
spectrum
intervent
pi
like
requir
discontinu
current
intervent
riskbas
decisionmak
framework
use
set
guid
principl
health
econom
assess
blood
safeti
intervent
end
day
dr
brian
custer
senior
investig
blood
system
research
institut
san
francisco
adjunct
professor
depart
laboratori
medicin
ucsf
gave
inform
lectur
econom
health
outcom
implic
introduc
new
blood
safeti
intervent
focu
pathogen
test
inactiv
technolog
dr
custer
began
present
introduc
audienc
three
main
concept
basi
econom
gener
health
econom
particular
first
concept
scarciti
stress
current
realiti
limit
resourc
budget
may
restrict
scope
servic
health
care
system
practition
abl
provid
second
concept
choic
choos
alloc
limit
resourc
avail
third
basic
econom
concept
opportun
cost
relat
next
best
altern
use
resourc
word
opportun
cost
benefit
willingli
forgon
choos
next
best
altern
three
notion
summar
challeng
decis
make
process
come
econom
inform
jurisdict
systemlevel
health
care
decis
made
use
differ
decisionmak
framework
district
health
author
resolv
problem
base
determin
health
prioriti
nation
region
target
clinic
research
data
health
expert
opinion
view
public
particip
exampl
fda
annual
track
data
fatal
relat
blood
collect
transfus
reaction
transmiss
diseas
http
wwwfdagov
microbi
fatal
transfus
track
use
variabl
expert
deem
import
focus
futur
pathogen
test
inactiv
effort
type
organ
blood
product
fatal
report
help
determin
rel
burden
fatal
differ
caus
result
shown
unit
state
plateletrel
death
mainli
caus
bacteria
red
cellrel
death
mainli
attribut
babesia
data
sourc
fda
fatal
data
help
health
author
understand
import
infect
risk
blood
recipi
face
respect
health
econom
blood
suppli
dr
custer
suggest
blood
suppli
aim
serv
public
good
achiev
aim
necessit
scarc
resourc
alloc
way
maxim
social
welfar
object
enumer
cost
benefit
consequ
altern
health
program
must
weigh
comparison
societi
ethic
belief
expect
resourc
alloc
align
well
valu
societi
alloc
certain
health
outcom
may
lead
friction
determin
health
prioriti
ultim
difficulti
decis
make
riskbas
decisionmak
framework
develop
allianc
blood
oper
intend
guid
assess
blood
safeti
intervent
integr
part
blood
system
riskmanag
program
riskbas
decisionmak
framework
two
compon
shown
figur
polici
foundat
decis
make
process
adher
framework
increas
consist
method
result
integr
contextu
issu
social
concern
legal
consider
decis
make
process
concept
qualiti
adjust
life
year
qali
develop
facilit
decis
make
establish
balanc
public
good
subject
qualit
outcom
resourc
alloc
object
quantit
outcom
qali
tool
measur
diseas
burden
includ
qualiti
quantiti
year
live
measur
medic
intervent
valu
money
scientist
may
make
variou
assumpt
measur
health
resourc
outcom
choos
wrong
outcom
choos
inappropri
test
measur
limit
well
incomplet
knowledg
base
lead
uncertainti
data
use
health
econom
analys
measur
health
cost
one
assum
expenditur
import
other
health
care
system
measur
consequ
intervent
one
assum
suffici
understand
risk
benefit
associ
intervent
cost
per
qali
provid
common
denomin
compar
intervent
reduc
uncertainti
introduc
unavoid
assumpt
establish
threshold
consid
costeffect
health
care
intervent
rang
qali
valu
us
dollar
blood
safeti
intervent
howev
consist
fall
well
threshold
good
exampl
nat
hiv
hcv
hbv
broad
rang
reflect
uncertainti
test
strategi
use
serolog
pcr
babesia
speci
wnv
nat
test
cruzi
antibodi
test
chaga
diseas
come
consid
pathogen
test
pi
outcom
interest
may
avail
aid
decis
make
exampl
qali
data
util
test
chikv
dengu
virus
hepat
e
viru
blood
safeti
context
avail
inform
econom
analysi
henc
understand
budget
impact
test
becom
difficult
hand
data
regard
babesia
test
avail
babesia
screen
endem
american
state
compar
univers
screen
use
qali
take
account
number
death
prevent
test
methodolog
use
also
qali
data
avail
support
practic
bacteri
test
platelet
pathogen
inactiv
plasma
data
estim
platelet
bacteri
test
costeffect
pathogen
inactiv
implement
costeffect
blood
donor
test
need
qali
appli
sever
patient
popul
sever
intervent
bell
et
al
compar
platelet
pi
use
intercept
leukemia
lymphoma
orthoped
cardiac
patient
author
found
new
method
cost
effect
qali
similar
accept
blood
safeti
intervent
mean
method
consid
costeffect
blood
safeti
context
preserv
patient
qualiti
life
dr
custer
colleagu
model
costeffect
pi
addit
current
pathogen
test
base
canadian
data
compar
mirasol
treatment
whole
blood
platelet
plasma
cost
per
qali
respect
cdn
instanc
shown
recent
costutil
analysi
implement
pi
poland
suggest
high
cost
better
costeffect
found
previou
analys
pi
nucleic
acid
test
north
america
pi
may
replac
intervent
current
incur
larg
cost
health
care
system
blood
irradi
bacteri
cultur
mainten
cmv
neg
inventori
pi
implement
remov
cost
associ
bacteri
cultur
irradi
could
result
reduct
costqali
pi
oper
gain
may
offset
invest
cost
includ
reduct
product
wastag
analys
base
assumpt
high
degre
uncertainti
result
potenti
use
blood
oper
move
era
pi
substanti
health
econom
analysi
allow
quantif
altern
comparison
intervent
differ
area
medicin
broad
implement
pi
blood
safeti
may
thu
prove
unpalat
funder
without
compensatori
cost
reduct
aspect
compon
product
either
focus
applic
pi
lack
implement
lowercost
altern
develop
may
ensu
decis
make
base
health
econom
risk
assess
like
becom
new
norm
blood
transfus
would
compris
strikingli
differ
approach
blood
safeti
implement
decis
make
past
novel
intervent
ad
older
one
sequenti
increas
cost
overal
blood
safeti
budget
shift
repres
move
toward
effect
transpar
manag
process
chang
rather
tradit
approach
reactiv
chang
respons
emerg
situat
disast
defend
blood
suppli
threat
transfusiontransmiss
infect
remain
high
prioriti
transfus
servic
canada
around
world
residu
risk
establish
pathogen
except
small
emerg
agent
greatest
concern
north
american
set
arbovirus
babesia
west
african
ebola
viru
epidem
reinforc
concern
environment
chang
fuel
rapid
emerg
pathogen
previous
thought
potenti
global
signific
pathogen
inactiv
blood
product
may
reduc
residu
risk
establish
agent
provid
protect
new
agent
medium
term
howev
like
driver
paradigm
shift
use
pathogen
inactiv
reduc
everpres
risk
bacteri
contamin
platelet
product
longer
term
possibl
donorfre
cellular
product
rapid
next
gener
sequenc
could
drive
transfusiontransmiss
rate
even
impress
safeti
margin
place
canada
develop
countri
health
econom
analysi
riskbas
decis
make
requir
determin
anticip
benefit
outweigh
consider
cost
potenti
step
annual
intern
symposium
receiv
fund
canadian
blood
servic
centr
innov
among
author
report
dr
geraldin
walsh
dr
mia
golder
dr
margaret
fearon
author
speaker
dr
william
sheffield
actual
potenti
conflict
interest
context
subject
program
past
five
year
dr
peter
schubert
author
speaker
disclos
grantresearch
support
terumobct
macopharma
among
speaker
dr
allison
mcgeer
nanci
angu
dr
samia
naccach
actual
potenti
conflict
interest
context
subject
program
past
five
year
follow
relationship
could
perceiv
relat
appar
conflict
interest
context
subject
program
past
five
year
disclos
dr
roger
dodd
grantresearch
support
grifol
ceru
consult
mosaiq
roch
dr
marc
turner
grantresearch
support
wellcom
trust
dr
brian
custer
grantresearch
support
grifol
formerli
novarti
holog
formerli
genprob
macopharma
member
speaker
bureau
terumobct
among
member
plan
committe
speaker
event
dr
kathryn
webert
dr
robert
skeat
dr
sophi
ahm
coovadia
sue
gregoir
actual
potenti
conflict
interest
relat
program
past
five
year
dr
ed
pryzdial
disclos
grantresearch
support
biogen
